The endothelin system and its role in pulmonary arterial hypertension (PAH)

被引：18

作者：

Pepke-Zaba, J ^{[1
]}

Morrell, NW

机构：

[1] Papworth Hosp, Pulm Vasc Dis Unit, Cambridge CB3 8RE, England

[2] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2QQ, England

来源：

THORAX | 2005年 / 60卷 / 06期

关键词：

D O I：

10.1136/thx.2004.031724

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：443 / 444

页数：2

共 16 条

[1] Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].

Barst, RJ ;

Ivy, D ;

Dingemanse, J ;

Widlitz, A ;

Schmitt, K ;

Doran, A ;

Bingaman, D ;

Nguyen, N ;

Gaitonde, M ;

van Giersbergen, PLM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382

[2] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[3] Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].

Barst, RJ ;

Rich, S ;

Widlitz, A ;

Horn, EM ;

McLaughlin, V ;

McFarlin, J .

CHEST, 2002, 121 (06) :1860-1868

[4] Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension [J].

Bauer, M ;

Wilkens, HC ;

Langer, F ;

Schneider, SO ;

Lausberg, H ;

Schäfers, HJ .

CIRCULATION, 2002, 105 (09) :1034-1036

[5] BQ123, AN ET(A)-RECEPTOR ANTAGONIST, ATTENUATES HYPOXIC PULMONARY-HYPERTENSION IN RATS [J].

BONVALLET, ST ;

ZAMORA, MR ;

HASUNUMA, K ;

SATO, K ;

HANASATO, N ;

ANDERSON, D ;

SATO, K ;

STELZNER, TJ .

AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (04) :H1327-H1331

[6] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].

Channick, RN ;

Simonneau, G ;

Sitbon, O ;

Robbins, IM ;

Frost, A ;

Tapson, VF ;

Badesch, DB ;

Roux, S ;

Rainisio, M ;

Bodin, F ;

Rubin, LJ .

LANCET, 2001, 358 (9288) :1119-1123

[7] The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats [J].

Chen, SJ ;

Chen, YF ;

Opgenorth, TJ ;

Wessale, JL ;

Meng, QC ;

Durand, J ;

DiCarlo, VS ;

Oparil, S .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (06) :713-725

[8] ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells [J].

Davie, N ;

Haleen, SJ ;

Upton, PD ;

Polak, JM ;

Yacoub, MH ;

Morrell, NW ;

Wharton, J .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) :398-405

[9] EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION [J].

GIAID, A ;

YANAGISAWA, M ;

LANGLEBEN, D ;

MICHEL, RP ;

LEVY, R ;

SHENNIB, H ;

KIMURA, S ;

MASAKI, T ;

DUGUID, WP ;

STEWART, DJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24) :1732-1739

[10] Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2 [J].

Humbert, M ;

Barst, RJ ;

Robbins, IM ;

Channick, RN ;

Galié, N ;

Boonstra, A ;

Rubin, LJ ;

Horn, EM ;

Manes, A ;

Simonneau, G .

EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (03) :353-359

← 1 2 →